Shamburg News · 8-K filed Nov 5, 2026, 4:13 PM EST
Inovio Pharmaceuticals Estimates Cash and Short-Term Investments of $48.4 Million at Sept. 30, 2026
INO · INOVIO PHARMACEUTICALS, INC.
- Earnings
- Materiality: medium
Inovio Pharmaceuticals, Inc. estimated that its cash, cash equivalents and short-term investments were approximately $48.4 million as of September 30, 2026. The figure is based on preliminary unaudited information and management estimates, is subject to completion of financial closing procedures, and has not been audited or reviewed by Ernst & Young LLP. The company furnished the information under Item 2.02 and noted that actual quarterly results may differ materially from the preliminary estimate.
Source: SEC EDGAR, Form 8-K, Item 2.02, accession 0001193125-26-449853.
Written from the filing by Shamburg Markets. Figures are as reported by the company.